Innate Pharma SA
PAR:IPH

Watchlist Manager

Innate Pharma SA

PAR:IPH

Watchlist

Dividends

Price: 1.94 EUR 0.83%

Market Cap: 157m EUR

Have any thoughts about
Innate Pharma SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication

Add Price Alert

Price Target:

Last Price: 1.94 EUR

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

IPH Alert

Innate Pharma SA

1.94

+0.016 (+0.83%)

52 Week Range	1.362 2.76
Price Target

We'll email you a reminder when the closing price reaches EUR.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Innate Pharma SA

What unique competitive advantages
does Innate Pharma SA hold over its rivals?

What risks and challenges
does Innate Pharma SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Innate Pharma SA.

What unique competitive advantages
does Innate Pharma SA hold over its rivals?

What risks and challenges
does Innate Pharma SA face in the near future?

Has there been any significant insider trading activity
in Innate Pharma SA recently?

Summarize the latest earnings call
of Innate Pharma SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Innate Pharma SA.

Provide P/S
for Innate Pharma SA.

Provide P/E
for Innate Pharma SA.

Provide P/OCF
for Innate Pharma SA.

Provide P/FCFE
for Innate Pharma SA.

Provide P/B
for Innate Pharma SA.

Provide EV/S
for Innate Pharma SA.

Provide EV/GP
for Innate Pharma SA.

Provide EV/EBITDA
for Innate Pharma SA.

Provide EV/EBIT
for Innate Pharma SA.

Provide EV/OCF
for Innate Pharma SA.

Provide EV/FCFF
for Innate Pharma SA.

Provide EV/IC
for Innate Pharma SA.

Show me price targets
for Innate Pharma SA made by professional analysts.

What are the Revenue projections
for Innate Pharma SA?

How accurate were the past Revenue estimates
for Innate Pharma SA?

What are the Net Income projections
for Innate Pharma SA?

How accurate were the past Net Income estimates
for Innate Pharma SA?

What are the EPS projections
for Innate Pharma SA?

How accurate were the past EPS estimates
for Innate Pharma SA?

What are the EBIT projections
for Innate Pharma SA?

How accurate were the past EBIT estimates
for Innate Pharma SA?

Compare the revenue forecasts
for Innate Pharma SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Innate Pharma SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Innate Pharma SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Innate Pharma SA compared to its peers.

Compare the P/E ratios
of Innate Pharma SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Innate Pharma SA with its peers.

Analyze the financial leverage
of Innate Pharma SA compared to its main competitors.

Show all profitability ratios
for Innate Pharma SA.

Provide ROE
for Innate Pharma SA.

Provide ROA
for Innate Pharma SA.

Provide ROIC
for Innate Pharma SA.

Provide ROCE
for Innate Pharma SA.

Provide Gross Margin
for Innate Pharma SA.

Provide Operating Margin
for Innate Pharma SA.

Provide Net Margin
for Innate Pharma SA.

Provide FCF Margin
for Innate Pharma SA.

Show all solvency ratios
for Innate Pharma SA.

Provide D/E Ratio
for Innate Pharma SA.

Provide D/A Ratio
for Innate Pharma SA.

Provide Interest Coverage Ratio
for Innate Pharma SA.

Provide Altman Z-Score Ratio
for Innate Pharma SA.

Provide Quick Ratio
for Innate Pharma SA.

Provide Current Ratio
for Innate Pharma SA.

Provide Cash Ratio
for Innate Pharma SA.

What is the historical Revenue growth
over the last 5 years for Innate Pharma SA?

What is the historical Net Income growth
over the last 5 years for Innate Pharma SA?

What is the current Free Cash Flow
of Innate Pharma SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Innate Pharma SA.

EV/EBITDA
Enterprise Value to EBITDA

-4.1

Current

-4.8

Median

4.2

Industry

Higher than median

Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA

-4.1

Enterprise Value

147.9m EUR

EBITDA

-36m EUR

All Countries

Forward Multiples

			Market Cap	EV/EBITDA
FR		Innate Pharma SA PAR:IPH	160.9m EUR	-4.1
FR		Pharnext SCA OTC:PNEXF	6T USD	-219 476
US		Abbvie Inc NYSE:ABBV	310.2B USD	15.2
US		Amgen Inc NASDAQ:AMGN	142B USD	16.1
US		Gilead Sciences Inc NASDAQ:GILD	115B USD	10.1
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	101.6B USD	20.8
US	E	Epizyme Inc F:EPE	94.1B EUR	-514.8
AU		CSL Ltd ASX:CSL	134.4B AUD	19.7
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	78.5B USD	15.3
US	S	Seagen Inc F:SGT	39.3B EUR	-58.8
NL		argenx SE XBRU:ARGX	36B EUR	-109.5

				EBITDA Growth	EV/EBITDA to Growth
FR		Innate Pharma SA PAR:IPH	Average EV/EBITDA: 16.2 Negative Multiple: -4.1	N/A	N/A
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -219 476	N/A	N/A
US		Abbvie Inc NYSE:ABBV	15.2	29%	0.5
US		Amgen Inc NASDAQ:AMGN	16.1	62%	0.3
US		Gilead Sciences Inc NASDAQ:GILD	10.1	16%	0.6
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	20.8	43%	0.5
US	E	Epizyme Inc F:EPE	Negative Multiple: -514.8	N/A	N/A
AU		CSL Ltd ASX:CSL	19.7	42%	0.5
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	15.3	35%	0.4
US	S	Seagen Inc F:SGT	Negative Multiple: -58.8	N/A	N/A
NL		argenx SE XBRU:ARGX	Negative Multiple: -109.5	N/A	N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBITDA

-3.1

2-Years Forward

EV/EBITDA

6.1

3-Years Forward

EV/EBITDA

3.1

	Franklin Covey Co NYSE:FC	36.1 USD -0.85%
	Mohawk Industries Inc NYSE:MHK	118.645 USD -0.43%
	Ardmore Shipping Corp NYSE:ASC	11.5 USD 1.68%
	ASGN Inc NYSE:ASGN	83.9 USD 0.04%
	Skyworks Solutions Inc NASDAQ:SWKS	89.99 USD 1.4%
	Weatherford International PLC NASDAQ:WFRD	67.725 USD 0.93%

	Johnson & Johnson NYSE:JNJ	143.55 USD -0.64%
	Bank of America Corp NYSE:BAC	43.795 USD -0.85%
	Mastercard Inc NYSE:MA	523.05 USD -0.95%
	Salesforce Inc NYSE:CRM	338.11 USD -1.61%
	Abbvie Inc NYSE:ABBV	175.14 USD -0.25%
	Home Depot Inc NYSE:HD	388.3 USD -1.1%

	Arista Networks Inc NYSE:ANET	112.415 USD -0.35%
	Visa Inc NYSE:V	314.22 USD -1.1%
	Texas Pacific Land Corp NYSE:TPL	1 126.655 USD -0.57%
	KLA Corp NASDAQ:KLAC	638.54 USD 1.46%
	Manhattan Associates Inc NASDAQ:MANH	277.71 USD -0.91%
	Pinduoduo Inc NASDAQ:PDD	99.525 USD 0.02%

	Salesforce Inc NYSE:CRM	338.11 USD -1.61%
	Accenture PLC NYSE:ACN	358.57 USD -2.13%
	ServiceNow Inc NYSE:NOW	1 081.455 USD -0.9%
	EOG Resources Inc NYSE:EOG	118.61 USD -0.36%
	Copart Inc NASDAQ:CPRT	57.94 USD -0.48%
	Applied Materials Inc NASDAQ:AMAT	166.155 USD 1.57%

Innate Pharma SA
PAR:IPH

EV/EBITDA
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Innate Pharma SA PAR:IPH

EV/EBITDA Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

Innate Pharma SA
PAR:IPH

EV/EBITDA
Enterprise Value to EBITDA